Immix Biopharma, Inc. IMMX Foreign currency translation gains (losses)
Foreign currency translation gains (losses) at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax.
The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s foreign currency translation gains (losses).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s foreign currency translation gains (losses)?
- Immix Biopharma, Inc. (IMMX) reported foreign currency translation gains (losses) of -$23.67K in Q1 2026.
- How has Immix Biopharma, Inc.'s foreign currency translation gains (losses) changed year-over-year?
- Immix Biopharma, Inc.'s foreign currency translation gains (losses) decreased by 243.3% year-over-year, from $16.52K to -$23.67K.
- What is the long-term trend for Immix Biopharma, Inc.'s foreign currency translation gains (losses)?
- Over 2 years (2023 to 2025), Immix Biopharma, Inc.'s foreign currency translation gains (losses) has grown at a 15.5% compound annual growth rate (CAGR), from $47.65K to $63.52K.
- What does foreign currency translation gains (losses) mean?
- This metric represents the net gains or losses resulting from the translation of financial statements of foreign subsidiaries from their functional currency into the reporting currency. It reflects the impact of exchange rate fluctuations on the value of international assets and liabilities. Investors monitor this to understand the volatility introduced by global operations that is excluded from net income.